DX07 Patient-Reported Outcomes After Fingolimod Switch: Early Consistent Benefit
Mark Cascione, Neetu Agashivala, Stanley Li, Luigi M. Barbato, Edward Kim

DX08 Treatment Selection in Multiple Sclerosis: Results of a Physician Survey
Kristin A. Hanson, Neetu Agashivala, Karina Raimundo, Edward Kim, Sonja M. Stringer, Zaneta Balanta

DX09 Fingolimod Efficacy and Safety vs. Placebo: Phase 3 FREEDOMS II Study
Mark Agius, Douglas Jeffery, Xiangyi Meng, Ron Hashmonay, Allitia DiBernardo

DX10 25-Hydroxyvitamin D and Multiple Sclerosis Activity During Therapy with Interferon Beta-1b
Alberto Ascherio, Kassandra Munger, Claire Simon, Ludwig Kappos, Chris H. Polman, Mark Freedman, Hans-Peter Hartung

DX11 Use of ACTHar Gel for Multiple Sclerosis Exacerbations During Natalizumab
Ronald O. Bailey, Randy R. Heim, Vu A. Nguyen, Carina G. Sprague

DX12 Natalizumab in Anti-JCV Seronegative Patients with Early Multiple Sclerosis
Roumen Balabanov, Jai Perumal, Robert J. Fox, Denise Campagnolo, Emese Dian, Stefan Lanker, Jennifer Sun

DX13 A Comparison of Two Health-Related Quality of Life Measures in Pediatric Demyelinating Disease
Austin Sye, E. Ann Yeh, Brenda Banwell, Christine Till

DX14 Preventing New Enhancing Lesions and Relapses After Discontinuing Tysabri
Tina Butterfield, Victor A. Maquera

DX15 Peginterferon Beta-1a via Autoinjector in Relapsing Multiple Sclerosis
Peter A. Calabresi, Serena Hung, Ali Seddighzadeh, Shifang Liu, Bjorn Spierling, Aaron Deykin

DX16 New Measures of Neurologic Disability Derived from NARCOMS Registry Data
Eric Chamot, Ilya Kister, Gary Cutter

DX17 Early Effect of Fingolimod on Clinical and MRI Outcomes in Relapsing Multiple Sclerosis
Peter Chin, Xiangyi Meng, Ron Hashmonay

DX18 Depression, Fatigue, and Clinical Improvements After Switch to Fingolimod
Mark Agius, Edward Kim, Stanley Li, Peter Chin, Ron Hashmonay, Neetu Agashivala

DX19 Joint Commission Disease-Specific Care Certification Process for Multiple Sclerosis
Jill M. Conway, Lindsey Belt, Michael Kaufman, Linda Moore, Marie Moore, Marlow Price, Lisa Smart, Donald Tesser

DX20 Improved Quality of Life After Therapy Change to Fingolimod
Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Neetu Agashivala, Lesley Schofield, Kevin McCague

DX21 Alemtuzumab’s Effects on Disability Outcomes Occur Early in Care-MS II

DX22 Novel Model of Care for the Person with Multiple Sclerosis
Allyn A. Danni

DX23 Multiple Sclerosis Patients Using RebiSmart™ Maintain Good Treatment Adherence: Measure Endpoints
Virginia Devonshire, Anthony Feinstein, Patrick Moriarty

DX24 Case Series of Cardiac Complications During Fingolimod First Dose Observation
Elizabeth M. R. Dragan, George J. Hutton, Yochai Birnbaum

DX25 Neuromyelitis Optica Presenting as Multiple Sclerosis Worsening on Natalizumab
Elizabeth M. R. Dragan, George J. Hutton

DX26 Efficacy of Fingolimod in Ethnic Minorities
Elizabeth M. R. Dragan, Toni Saldana-King, George J. Hutton

DX27 Patient-Reported Experience Measures and Outcomes in Multiple Sclerosis
Nikki Embrey, Delyth Thomas, Laura Parkes

DX28 Predictors of Successful Acceptance of Home Telemanagement in Multiple Sclerosis
Joseph Finkelstein, Eunme Cha, Mitchell T. Wallin

DX29 Treatment Satisfaction and Clinical Improvement After Switch to Fingolimod
Edward Fox, Keith Edwards, J. Gordon Burch, Edward Kim, Linda Pestreich, Kevin McCague, Luigi M. Barbato
DX30  First Case of Immune Thrombocytopenia in the CAMPATH Extension Trial (CAMMS03409)  
Malcolm H. Gottesman, Shicong Ye, John Delmonte Jr., Abigail McNall, Kimberly Byrnes, Eileen Boylan

DX31  Values and Challenges of Multiple Sclerosis Specialist Certification  
Elsie E. Gulick

DX32  Data Management and Monitoring in the CombiRx Randomized Trial  
Tarah Gustafson, C. Steve Powell, Amber Salter, Jing Wang, Fred D. Lublin, Jerry Wolinsky, Robin Comstock

DX33  Prolonged Enhancement of a Demyelinating Lesion Mimicking Lymphoma  
Paula Hardeman, Elliot Frohman, Benjamin Greenberg

DX34  Study Design of a Multinational Gilenya™ (Fingolimod) Pregnancy Exposure Registry  
Yvonne Geissbuehler, Estel Plana Hortoneda, Ron Hashmonay, Simrat Randhawa

DX35  Cardiac Effects of Fingolimod in Patients with Multiple Sclerosis  
Bruce L. Hughes, Mark Cascione, Kevin McCague, Linda Pestreich, Lesley Schofield, Edward Kim, Luigi Nardone

DX36  Patient on Natalizumab for Multiple Sclerosis: Earworms or Musical Hallucinations  
Farhat Husain, Jeremy Levin, Cecillie Fieldstad

DX37  Effect of Fingolimod on Brain Atrophy: MRI Data from Phase 3 Studies  
Douglas Jeffery, Jeffrey A. Cohen, Xiangyi Meng, Ron Hashmonay

DX38  Durable Effects of Alemtuzumab on Relapse Rate over Time in CARE-MS III  
Lily Jung Henson, Douglas L. Arnold, Jeffrey A. Cohen, Alasdair J. Coles, Christian Confavreux, Edward J. Fox

DX39  Pregnancy Outcomes with Teriflunomide: Female Patients and Partners of Men  
Lily Jung Henson, Olaf Stuve, Myriam Benamor, Sandrine Turpault, Francois Menguy-Vacheron

DX40  Time Course of Treatment Effects of BG-12 (Dimethyl Fumarate) in Multiple Sclerosis  
Ludwig Kappos, Gavin Giovannoni, Ralf Gold, J. Theodore Phillips, Christophe Hotermans, Annie Zhang

DX41  Efficacy of Glatiramer Acetate 40-mg Injection Three Times Weekly  
Omar Khan, Peter Reckmann, Alexey Boyko, Krzysztof Selmaj, Robert Zvadinov

DX42  Prospective, Longitudinal Study of Natalizumab Treatment in Multiple Sclerosis  
Ellen Lathi

DX43  Patient-Reported Outcomes in Primary Progressive Multiple Sclerosis  
Christine Manella, Deborah Backus, Blake Burdette

DX44  Considerations for Implementing a Health and Wellness Program for People with Multiple Sclerosis  
Ruth Ann Marrie, Luanne Metz, Katayoun Alikhani, Gregg Blevins, Jacqueline Bakker, Larry Svenson, Nuala O’Leary

DX45  CCSVI Treatment and Comorbidity: A Province-Wide Study of Multiple Sclerosis  
Sarah M. Militello

DX46  Best Practice for Education and Ongoing Evaluation of Patients on Gilenya and Fingolimod  
Heidy Russell, John O’Gorman, Jie Li, Glenn Phillips, Vissia Viglietta

DX47  Combination Interferon Beta-1a and Mycophenolate Mofetil in Relapsing-Remitting Multiple Sclerosis  
Jacqueline A. Nicholas, Yuhong Yang, Caroline Schaffer, Morgan Savel, Kyle Porter, Claudia Kirsch, Michael Balcer-Lynn

DX48  Implementation of a Quality Improvement Program in a Multiple Sclerosis Clinic  
Margie O’Leary, Rock Heyman, Ryan Orie, Galen Mitchell, Islam Zaydan, Rebecca Rosiek, Victoria Young

DX49  Effect of BG-12 (Dimethyl Fumarate) in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis  
J. Theodore Phillips, Ralf Gold, Gavin Giovannoni, Robert J. Fox, Annie Zhang, Leslie Meltzer, Nuwan C. Kurukulasuriya

DX50  Cardiac Effects of Fingolimod: First-Dose Observation  
Simrat Randhawa, Xiangyi Meng, Ron Hashmonay

DX51  JC Virus Antibody Index Stratifies PML Risk in Natalizumab-Treated Multiple Sclerosis  
Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian O’Gorman

DX52  BG-12 (Dimethyl Fumarate) with Aspirin Pretreatment or Slow Dose Titration  
Heidy Russell, John O’Gorman, Jie Li, Glenn Phillips, Vissia Viglietta

2 / 3
DX53 Persistence and Treatment Satisfaction in Patients Using the AVONEX PEN
Bjorn Sperling, Sergio Slawka, Christina Ghaus, Xiaojun You

DX54 Switching to Fingolimod or Interferon Beta-1a: A Cost-Effectiveness Analysis
Kangho Suh, Neetu Agashivala, Edward Kim

DX55 Long-Term Safety and Tolerability of Fingolimod in Relapsing-Remitting Multiple Sclerosis
Reinhard Hohlfeld, Xiangyi Meng, Ron Hashmonay, Nadia Tenenbaum

DX56 Predictors of Switching First-Line Disease-Modifying Therapy for Multiple Sclerosis
Barbara E. Teter, Neetu Agashivala, Katelyn S. Kavak, Lynn Chouhfeh, Ron Hashmonay, Bianca Weinstock-Guttman

DX57 Development of a Care Pathway for Patients with Suspected PML
Karen Vernon, William Lusher, Fran Jackson, David Rog

DX58 Teriflunomide in Routine Clinical Practice: Design of the Teri-PRO Study
Timothy L. Vollmer, Aline Stalla-Bourdillon, Miqun Robinson

DX59 Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire: Pilot Study
Alona Williamson, Tracy Flemming Tracy, Jennifer Smrtka, Carol Saunders, Constance B. Easterling, Amy Perrin Ross

DX60 Herpes Infection Risk Reduced with Acyclovir Prophylaxis After Alemtuzumab

DX61 High Monthly T2 Lesion Burden Associated with Improved EDSS Score upon Starting Multiple Sclerosis Treatment
Charles C. Yu, Samantha Lancia, Nhial Tutlam, Junqian Xu, Robert T. Naismith

DX62 Measuring Adherence of Tecfidera®
Lise Casady, Angela M. Aungst, Derrick S. Robertson, Sean M. Masi

DX63 Rescaling the EDSS Using Rasch Analysis
William J. Culpepper II, Mitchell T. Wallin